If it's a safer beta blocker it would make a good candidate for higher-risk hypertension patients (diabetes, obesity, CHF, COPD) and that's what FRX is trying to prove in many ongoing phase IV trials for Bystolic.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.